key: cord-0872867-c7c9ycew
authors: Killikelly, April M.; Kanekiyo, Masaru; Graham, Barney S.
title: Pre-fusion F is absent on the surface of formalin-inactivated respiratory syncytial virus
date: 2016-09-29
journal: Sci Rep
DOI: 10.1038/srep34108
sha: 75a8ca179e8e0405a9c150507809c0f5c38aedb5
doc_id: 872867
cord_uid: c7c9ycew

The lack of a licensed vaccine for respiratory syncytial virus (RSV) can be partly attributed to regulatory hurdles resulting from vaccine enhanced respiratory disease (ERD) subsequent to natural RSV infection that was observed in clinical trials of formalin-inactivated RSV (FI-RSV) in antigen-naïve infants. To develop an effective vaccine that does not enhance RSV illness, it is important to understand how formalin and heat inactivation affected the antigenicity and immunogenicity of FI-RSV compared to native virus. Informed by atomic structures of RSV fusion (F) glycoprotein in prefusion (pre-F) and postfusion (post-F) conformations, we demonstrate that FI-RSV predominately presents post-F on the virion surface, whereas infectious RSV presents both pre-F and post-F conformations. This significant antigenic distinction has not been previously appreciated. Thus, a stabilized pre-F antigen is more representative of live RSV than F in its post-F conformation, as displayed on the surface of FI-RSV. This finding has major implications for discriminating current pre-F-based immunogens from FI-RSV used in historical vaccine trials.

infection in antigen-naïve young infants, it is important to understand how viral inactivation affected antigenicity and immunogenicity of FI-RSV compared to native virus.

Formalin (aqueous formaldehyde) treatment is a long-established method to inactivate viruses. At high concentrations (1%), formalin fixes tissue and obliterates infectivity by forming chemical additions (carbonyls) and intra-and inter-protein crosslinking 13 . At lower concentrations, however, these modifications have a varied effect on preserving antigenic sites. Hepatitis A virus vaccine that was inactivated with 0.0625% formalin elicited antibodies in humans that neutralized virus and protected against infection 14, 15 . However, poliovirus that was inactivated with 0.025% formalin was shown to have decreased binding to the human poliovirus receptor, suggesting that formalin inactivation had altered the receptor-binding site 16 . These data suggest that formalin can potentially "fix" or stabilize protein conformation, alter protein structure, and/or chemically modify protein surfaces. Until now it was unknown how the heat and formalin treatment used to produce FI-RSV would affect the conformation and antigenic content of the RSV fusion glycoprotein (F) on virion surfaces.

The surface of RSV is decorated with surface proteins, including the fusion protein (F), the attachment protein (G) and the small hydrophobic (SH) pentameric ion channel. While G may play a role in attachment to airway epithelium and immunomodulation, the F glycoprotein is the major target for vaccine development due to its requirement for viral entry and high sequence conservation. F is a type I transmembrane protein cleaved by furin-like proteases into F1 (AA 137-574), peptide 27 (AA 110-138) and F2 (AA 1-109) that form a trimer of F1-F2 heterodimers. Atomic-level structures of F have been determined in two distinct conformations, prefusion and postfusion [17] [18] [19] (pre-F and post-F, respectively) ( Fig. 1a,b) . Similarly to other class I fusion proteins, RSV F undergoes a massive conformational rearrangement to mediate viral-cell membrane fusion, transitioning irreversibly from a metastable pre-F to a stable post-F conformation. Although pre-F and post-F structures have distinct shapes, they share roughly 50% of their surface area, including two well-defined antigenic sites (II and IV) that are moderately neutralization sensitive. On the unique surfaces of pre-F there are at least three additional antigenic sites reported so far (Ø, III, and V) that are highly neutralization sensitive, particularly site Ø (Fig. 1b) . Antibodies that bind antigenic site I have weak or no neutralizing activity and bind almost exclusively to post-F. Both pre-F and post-F are present in the membrane of infectious RSV, but neutralizing antibody responses found in naturally infected individuals > 5 years of age are predominantly directed towards pre-F surfaces 20 . To have significant neutralizing activity, RSV F-specific antibodies have to recognize and interrupt pre-F function 21 .

At the time of FI-RSV production and clinical evaluation, it was thought that although formalin treatment would render RSV non-infectious, it would not interfere with the antigenic properties of the virus. Studies later showed that FI-RSV induced relatively high titres of binding antibodies, but with low neutralizing activity 7,8 , hinting that FI-RSV may not be recapitulating the antigenic surfaces of infectious RSV. Structural analyses detailing the epitopes of monoclonal antibodies (mAbs) binding to pre-F and post-F have yielded tools that make it Figure 2 . Assessing the stability of pre-F during FI-RSV production. (a) Dot blots demonstrate motavizumab recognition of antigenic site II, AM14 recognition of quaternary antigenic site V, and D25 and 5C4 recognition of antigenic site Ø after RSV is incubated at 37 °C with a 0.025% concentration of formalin in 24-hour intervals. Average antibody binding of virions is reported relative to antibody binding of a pre-F protein loading control with error bars representing standard deviation of three experiments. Significant differences between populations are calculated by One-Way ANOVA and noted graphically (ns, not significant; *p ≤ 0.05; **p ≤ 0.01; ***p ≤ 0.001; ****p ≤ 0.0001). Recognition of antigenic site II, present on both pre-F and post-F surfaces, is preserved after treatment with high temperature and a dilute concentration of formalin. In contrast, dot blots demonstrate pre-F-specific mAbs AM14, D25 and 5C4 rapidly lose reactivity against virions incubated at 37 °C with a dilute concentration of formalin. 

Antigenic characterization by dot blot using mAbs that either target antigenic site II on the shared surface between pre-F and post-F (motavizumab) or epitopes unique to pre-F (D25, 5C4, and AM14) 21, 22 (Fig. 1b) showed that all four antibodies recognized freshly purified RSV, but FI-RSV was only recognized by motavizumab (Fig. 1c) . In the experiments using a conformationally stabilized prefusion F protein (DSCav1), pre-F specific antibodies were able to recognize DSCav1 after incubation at 37 °C with or without the addition of 0.025% formalin. This indicates that the loss of recognition of FI-RSV by pre-F specific antibodies is not due to chemical modifications by formalin, but rather due to modifications of pre-F conformation. To investigate the effect of formalin on antigenic recognition, we increased the concentration of added formalin to 1% and found that the recognition of post-F by motavizumab and DSCav1 by all antibodies were greatly reduced ( Supplementary Fig. 1 ). This indicates that formalin can influence antigenicity, but the effect is not discernable at the "formalin-inactivating" concentration of 0.025%, and is much less than the impact of temperature. To further understand the effect of formalin and elevated temperature on the antigenic profile of RSV virions, we recapitulated the methods used to manufacture FI-RSV and defined the kinetics of antibody reactivity. Immediately after the application of formalin, RSV retained both pre-F and post-F antigenic sites; however, over time at 37 °C, pre-F specific epitopes on the surface of RSV disappear (Fig. 2a) . The disappearance of pre-F specific epitopes (particularly site Ø) correlated with reduction in infectivity, as determined by flow cytometry of recombinant GFP-expressing RSV-infected cells (Fig. 2b) .

A similar correlation of diminished AM14 trimer binding and loss of infectivity was observed for virus incubated at different temperatures ranging from 25 °C to 37 °C in the presence of 0.025% formalin (Fig. 3a,b) . While reactivity with motavizumab remains relatively stable at every temperature, virus incubated at close to room temperature (25 °C) maintains pre-F epitopes (AM14, D25, 5C4 binding) longer than viruses incubated at human body temperature (37 °C) or mouse body temperature (39 °C). These data indicate that pre-F on the surface of virions is converted to post-F more quickly at temperatures above room temperature; and that after 72 hours at 36 °C, the original FI-RSV had no remaining pre-F.

As a class I fusion protein, RSV F shares properties with surface glycoproteins of other enveloped viruses such as parainfluenza virus fusion (F), influenza hemagglutinin (HA), HIV-1 envelope (Env), Ebola glycoprotein (GP) and coronavirus spike (S). These proteins all mediate membrane fusion by a conformational change from a prefusion form to a transitional pre-hairpin intermediate form and eventually to a stable 6-helix bundle postfusion form. Therefore, defining the protein conformation presented on the surface of a viral immunogen is key to understanding mechanisms of antibody neutralization, and represents an important step toward designing a vaccine immunogen targeting the functional prefusion conformation. Recent work on HIV-1 Env has demonstrated that, in contrast to strain-specific antibodies raised against gp120 monomers or non-native trimeric gp140, stabilized versions of the prefusion Env trimer can preferentially elicit conformation-dependent, cross-reactive antibodies that can effectively target a functional prefusion conformation 23 . Similarly, the critical differences between antigenic sites of pre-F on infectious RSV and post-F on FI-RSV suggest that the balance of F conformational states determines virus infectivity. Designing immunogens that preserve neutralization-sensitive epitopes on the functional form of viral proteins will promote the induction of protective antibody responses and diminish non-neutralizing antibody responses, theoretically reducing the likelihood of immune complex formation and complement activation.

Studies in mice and macaques have shown that stabilized pre-F immunogens elicit potent neutralizing antibody responses with titers at the high end of what is achieved after recurrent natural infections in humans 21 . By 72 hours, the time used to make the FI-RSV vaccine, the presence of pre-F-specific epitopes on the virion surface of the membrane was nearly completely lost (Fig. 4) . This contradicts the original presumption that production of FI-RSV from RSV alters only the infectivity of the virus, not the antigenicity, and that this low concentration of formalin would help preserve or fix the antigenic sites on the virus 24 .

The catastrophic failure and tragedy resulting from the FI-RSV vaccine trails has restricted consideration for using protein-based RSV vaccines in antigen-naïve infants. Defining the atomic-level detail of RSV F in two distinct conformations as well as isolation and characterization of mAbs that can distinguish surfaces unique to the functional pre-F from those on non-functional post-F, provides new reagents to define the antigenicity of FI-RSV and an additional piece of the FI-RSV-induced vaccine-enhanced disease puzzle. We anticipate that vaccine design based on understanding the relationship between conformational state and specificity of immune responses will guide the development of effective vaccines against RSV and potentially other viral diseases. 

Antigenic Analysis. Antigenic characterization was performed by dot blot using mAbs that either target antigenic site II on the shared surface between pre-F and post-F (motavizumab) or epitopes unique to pre-F surfaces (D25, 5C4, and AM14) 21, 22 . Briefly, dots of pre-F, post-F, heat inactivated pre-F (HI-Pre-F), formalin inactivated pre-F (FI-Pre-F), RSV or FI-RSV are applied to a nitrocellulose membrane, probed with antibodies motavizumab, AM14, D25 and 5C4 (made in house) similarly to a Western blot and probed with an HRP-conjugated secondary antibody reactive against either human (goat anti-human IgG-HRP, Santa Cruz Biotechnology) or mouse (rabbit anti-mouse IgG-HRP, Jackson Immunoresearch) Fc regions 25 . Both HI-and FI-Pre-F are incubated at 37 °C for 96 hours, FI-Pre-F includes a 0.025% concentration of formalin and 1% Pre-F includes a 1% concentration of formalin. Antibodies are incubated for one hour at room temperature in 5% skim milk in TBS-T at a concentration of 0.2 μg/mL. Antibody binding is detected via a G-box gel imager (Syngene) and densitometry done using Genetools (Syngene). Antibody binding to post-F and virions is reported relative to antibody binding of a pre-F protein loading control.

Time Course Analysis. The manufacture of FI-RSV required RSV to be exposed to a 0.025% formalin for 72 hours at 36 °C. We produced FI-RSV by incubating RSV with 0.025% formalin at 37 °C for up to 96 hours. Viruses are sampled for antigenic analysis and infectivity every 24 hours over a 96 hour-interval after incubation at 25 °C, 30 °C, 37 °C or 39 °C.

Infectivity. RSV expressing GFP (A2 strain) was incubated at 37 °C with a 0.025% concentration formalin and sampled periodically to infect HEp-2 cells 26 . Infection was monitored as a function of GFP expression (encoded by the viral genome) at 18 hours post-infection by flow cytometry (LSR II, BD Bioscience, CA, USA). Prior to assessment by flow cytometry, cells were treated with 4 mM EDTA to ensure a single-cell suspension optimal for analysis and fixed with 0.5% paraformaldehyde. One hundred percent infectivity represents the number of cells infected by RSV with no prior incubation.

Challenges and opportunities for respiratory syncytial virus vaccines

An Overview of Respiratory Syncytial Virus

Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine

An epidemiologic study of altered clinical reactivity to respiratory syncytial (RS) virus infection in children previously vaccinated with an inactivated RS virus vaccine

Respiratory virus immunization. I. A field trial of two inactivated respiratory virus vaccines; an aqueous trivalent parainfluenza virus vaccine and an alum-precipitated respiratory syncytial virus vaccine

Field evaluation of a respiratory syncytial virus vaccine and a trivalent parainfluenza virus vaccine in a pediatric population

Formalin-inactivated respiratory syncytial virus vaccine induces antibodies to the fusion glycoprotein that are deficient in fusion-inhibiting activity

Effect of age and preexisting antibody on serum antibody response of infants and children to the F and G glycoproteins during respiratory syncytial virus infection

A Role for Immune Complexes in Enhanced Respiratory Syncytial Virus Disease

RSV vaccine-enhanced disease is orchestrated by the combined actions of distinct CD4 T cell subsets

The absence of enhanced disease with wild type respiratory syncytial virus infection occurring after receipt of live, attenuated, respiratory syncytial virus vaccines

Parenteral administration of live respiratory syncytial virus vaccine: results of a field trial

A potential molecular mechanism for hypersensitivity caused by formalin-inactivated vaccines

Clinical experience with an inactivated hepatitis A vaccine

Safety and effectiveness of the new inactivated hepatitis A virus vaccine

Effect of Formaldehyde Inactivation on Poliovirus

Neutralizing epitopes on the respiratory syncytial virus fusion glycoprotein

A highly stable prefusion RSV F vaccine derived from structural analysis of the fusion mechanism

Structure of respiratory syncytial virus fusion glycoprotein in the postfusion conformation reveals preservation of neutralizing epitopes

Prefusion F-specific antibodies determine the magnitude of RSV neutralizing activity in human sera

Structure-Based Design of a Fusion Glycoprotein Vaccine for Respiratory Syncytial Virus

Characterization of a Prefusion-Specific Antibody That Recognizes a Quaternary, Cleavage-Dependent Epitope on the RSV Fusion Glycoprotein

HIV-1 neutralizing antibodies induced by native-like envelope trimers

Disinfection and Sterilization

Dot-blot nitrocellulose enzyme immunoassays for the detection of white-spot virus and yellow-head virus of penaeid shrimp

A flow cytometry-based assay to assess RSV-specific neutralizing antibody is reproducible, efficient and accurate

We thank Alan Hoofring for assistance with graphic artwork, Jason McLellan (Dartmouth College), Tracy Ruckwardt, Kaitlyn Morabito, Joan Ngwuta and members of the Viral Pathogenesis Laboratory for advice and comments. This work was supported by the Intramural Program of the Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health.

A.M.K. performed the experiments and wrote the manuscript in close consulation with M.K. and B.S.G.